semaglutide 1.0 mg was discontinued before the last dose because of use of prescription or non-prescription systemic products or topical medicinal products within 3 weeks prior to the visit' and one subject randomised to placebo was discontinued after the last dose because of a serious AE (traffic accident
Special typesGLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonistsplay a vital role in controlling appetite, managing blood sugar, and metabolizing fats
Improved metabolic health: In addition to weight loss, Mounjaro helps to reduce the risk of obesity-related health conditions, including type 2 diabetes, high blood pressure, and cardiovascular disease
Fatigability: A prognostic indicator of phenotypic aging
Tirzepatide does not [yet] have this data. Ozempic lowers A1C levels, aids in weight loss and reduces the risk of cardiovascular events in people with established cardiovascular diseases